• Time of issue:2022-06-13 19:10

(Summary description)Innovation, openness, integration, win-win partnership Guangzhou Lab led by Zhong Nanshan signed a cooperation agreement with Microbio (Shanghai), Livzon Pharmaceutical, and other four pharmaceutical companies for COVID-19 drug development   In the morning of June 10, the 14th China Bioindustry Convention opened on Guangzhou International Bio Island. At the high-level forum, Zhong Nanshan, chairman of the convention, winner of the Medal of the Republic, and academician of the Chinese Academy of Engineering, delivered a speech themed "scientific pandemic control for public health and sound economic development". In his speech, Zhong Nanshan discussed hot issues and development trends in global public health, human health, and China's national biosafety risk control and governance system. In addition, he introduced the representative COVID-19 vaccines and drugs developed by the Chinese companies participating in the signing ceremony. Zhong said that representative COVID-19 drugs under development in China included 3CLpro inhibitor, siRNA, Chinese herbal monomer, and antibody-based drugs. Guangzhou Lab under his leadership was working on five new COVID-19 drugs, some of which were jointly developed with other institutes and leading the industry in terms of development progress. He also made objective comments on achievements of some well-known research institutes and enterprises in this field.